Fig 2: Principal component analysis and differentially expressed genes in AKR1B10hi leiomyomas.a Thirteen AKR1B10hi leiomyomas and seven corresponding myometrium samples were analyzed together with a previously published dataset of 44 leiomyoma and 5 myometrium samples. Principal component analysis revealed that the AKR1B10hi samples cluster separately from leiomyomas of the MED12, HMGA2, and FH subtypes. Samples analyzed in this study are marked with sample identifiers. b AKR1B10 was significantly upregulated in AKR1B10hi and FH-deficient leiomyomas, but not in the other leiomyoma subtypes. c Deubiquitination gene UCHL1 was among the most uniquely upregulated genes in AKR1B10hi leiomyomas.

Fig 3: Comparison of Kaplan–Meier curves of 5-year DFS and OS rates between GC patients with overexpression and low expression of AKR1B10. Adjuvant chemotherapy subgroup: (A) DFS and (B) OS; signet ring cell carcinoma subgroup: (C) DFS and (D) OS; pathological stage I subgroup: (E) DFS and (F) OS.

Fig 4: Kaplan–Meier curves comparing 5-year disease-free survival (DFS) and overall survival (OS) rates in GC patients with overexpression or low expression of AKR1B10. (A) DFS; (B) OS.

Fig 5: The immunohistochemical analysis of AKR1B10 in gastric cancer patients who received gastrectomy with D2 lymph node dissection.